Who
Derek DiRocco
Director
Company insider
Files Form 4 as: Director, Acrivon Therapeutics; Director, Mineralys Therapeutics; Director, 89bio; Director, Werewolf Therapeutics; Director, iTeos Therapeutics.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 5 Apr 2020
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,366 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,366 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,200 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —7,000 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —7,000 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —12,500 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —25,000 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —27,400 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —45,150 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —56,400 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 13 Feb 2025filed 24 Feb 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,900 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | 89biooption or derivative | SEC FORM 4 Code A | —56,400 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 24 May 2024filed 24 May 2024 | HOWL Werewolf Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.